THE WHAT? Unilever has announced its results for fiscal 2021. The UK-based FMCG manufacturer reported underlying sales growth of 4.5 percent, its steepest incline in nine years.
THE DETAILS Turnover was up 3.4 percent and underlying operating profit increased 2.9 percent. Underlying EPS inched forward 5.5 percent.
The manufacturer of Dove announced the sale of its tea business for €4.5 billion too, with completion slated for the second half of the year. In addition, it backpaddled on previous plans to pursue a major acquisition, instead Unilever will pursue a share buyback programme of up to €3 billion over the next two years in an attempt to placate shareholders who were up in arms over the owner of Lifebuoy’s bid for GSK’s consumer unit.
THE WHY? CEO, Alan Jope commented, “The acceleration of Unilever’s operating performance continues. We delivered our fastest underlying sales growth for nine years – 4.5 percent for the full year, with 1.6 percent from volume.
“Our thirteen billion-Euro brands grew 6.4 percent. Priority markets of China, India, and the US grew at 14.3 percent, 13.4 percent, and 3.7 percent respectively. Our growth in e-commerce was 44 percent, ahead of global channel growth and bringing e-commerce to 13 percent of turnover. We have continued to re-shape our portfolio into high growth spaces, acquiring in Prestige Beauty and Functional Nutrition, and agreeing the sale of our Tea business.
“The major challenge of 2021 has been the dramatic rise of input costs. We responded with pricing actions, delivering underlying price growth of 2.9 percent for the year, accelerating to 4.9 percent in the fourth quarter, with full year underlying operating margin down 10bps and underlying earnings per share up 5.5 percent.”
Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.
Key aspects of aesthetic injectable companies include:
-
Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.
-
Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.
-
Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.
-
Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.
-
Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.
